Enhancing preclinical predictivity

IMMUNO-ONCOLOGY INSIGHTS

July 2021

Enhancing preclinical predictivity

Download PDF

Foreword

Enhancing preclinical predictivity: what is going wrong between preclinical <em>in vitro/in vivo</em> and clinical in vivo settings?

Enhancing preclinical predictivity: what is going wrong between preclinical in vitro/in vivo and clinical in vivo settings?

Christian Schmees

Editorial

Microphysiological systems for immuno-oncology: opportunities and challenges

Microphysiological systems for immuno-oncology: opportunities and challenges

Expert Insight

Advancement of precision oncology by integration of highly sensitive protein profiling technologies and patient-derived cell models for functional efficacy testing

Advancement of precision oncology by integration of highly sensitive protein profiling technologies and patient-derived cell models for functional efficacy testing

Michael Pawlak, Markus Templin, Christian Schmees

Interview

Recent evolution in the bispecific antibody and engineered cytokine fields

Recent evolution in the bispecific antibody and engineered cytokine fields

Translational R&D insights for the allogeneic CAR T cell therapy field and beyond

Translational R&D insights for the allogeneic CAR T cell therapy field and beyond

Expert Roundtable Video

Enhancing preclinical predictivity in I-O: what is going wrong between preclinical <em>in vitro/in vivo</em> and clinical settings?

Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?

P Ellmark, D Gilham, M Steegmaier et al.

Expert Roundtable

Enhancing preclinical predictivity in I-O: what is going wrong between preclinical <em>in vitro/in vivo</em> and clinical settings?

Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?